TerminatedPhase 1/2

A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer

United Kingdom79 participantsStarted 2014-01

Plain-language summary

The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Dosing was changed within 6 weeks before Screening or
✕. The patient's cancer is responding to glucocorticosteroid intake

What they're measuring

Maximum tolerated dose / Recommended Phase 2 dose; Tolerability

Timeframe: after 2 or 6 weeks depending on study part; continously

Trial details

NCT IDNCT02042885

SponsorOtsuka Novel Products GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-02

View on ClinicalTrials.gov More Prostate Cancer trials